Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 2, 2010, Pages 186-193

  Van Vonderen, Marit G A ^a   Blümer, Regje M E ^b   Hassink, Elly A M ^c   Sutinen, Jussi ^d   Ackermans, Mariette T ^b   Van Agtmael, Michiel A ^a   Yki Jarvinen, Hannele ^d   Danner, Sven A ^a   Serlie, Mireille J ^b   Sauerwein, Hans P ^b   Reiss, Peter ^b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c International Antiviral Therapy Evaluation Center   (Netherlands)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Antiretroviral therapy; Glucose metabolism; HIV; HIV associated lipodystrophy

Indexed keywords

GLUCOSE; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STABLE ISOTOPE;

ADULT; AGED; ARTICLE; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT BODY; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERINSULINEMIA; INHIBITION KINETICS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOLYSIS; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; ANTI-HIV AGENTS; BLOOD GLUCOSE; BODY COMPOSITION; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LAMIVUDINE; LIPIDS; LIPOLYSIS; LIVER; MALE; MIDDLE AGED; ZIDOVUDINE;

EID: 75649125598     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181c190f4     Document Type: Article

References (32)

1. Van der Valk M, Bisschop PH, Romijn JA, et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS. 2001;15:2093-2100.
2. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002;16:F1-F8.
3. Lee GA, Lo JC, Aweeka F, et al. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006;43:658-660.
4. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18:2137-2144.
5. Noor MA, Flint OP, Maa JF, et al. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS. 2006;20:1813-1821.
6. Shankar SS, Considine RV, Gorski JC, et al. Insulin sensitivity is preserved despite disrupted endothelial function. Am J Physiol Endocrinol Metab. 2006;291:E691-E696.
7. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641-649.
8. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study. J Acquir Immune Defic Syndr. 2008;49:369-376.
9. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS. 2007;21:1739-1745.
10. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292:E1666-E1673.
11. Blumer RM, van Vonderen MG, Sutinen J, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008;22:227-236.
12. Serlie MJ, Allick G, Groener JE, et al. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance. J Clin Endocrinol Metab. 2007;92: 166-171.
13. van der Valk M, Reiss P, van Leth FC, et al. Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. J Clin Endocrinol Metab. 2002;87:5066-5071.
14. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006;55(Suppl 2):S9-S15.
15. Mattacks CA, Sadler D, Pond CM. Site-specific differences in the action of NRTI drugs on adipose tissue incubated in vitro with lymphoid cells, and their interaction with dietary lipids. Comp Biochem Physiol C Toxicol Pharmacol. 2003;135:11-29.
16. Rudich A, Vanounou S, Riesenberg K, et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes. 2001;50:1425-1431.
17. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res. 2000;47:121-129.
18. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci. 2005;26:88-93.
19. Lagathu C, Eustace B, Prot M, et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12:489-500.
20. Balasubramanyam A, Sekhar RV, Jahoor F, et al. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of'systemic steatosis'. Curr Opin Lipidol. 2004;15:59-67.
21. Addy CL, Gavrila A, Tsiodras S, et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab. 2003;88:627-636.
22. Mynarcik DC, Combs T, McNurlan MA, et al. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. JAcquir Immune Defic Syndr. 2002;31:514-520.
23. Hadigan C, Kamin D, Liebau J, et al. Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. Am J Physiol Endocrinol Metab. 2006;290:E289-E298.
24. Shankar SS, Degawa-Yamauchi M, Considine RV et al. Indinavir-associated endothelial dysfunction is associated with increased plasma adiponectin levels. Presented at: 5th International Workshop on adverse drug reactions and lipodystrophy in HIV; July 8-11, 2003, Paris, France. Abstract.
25. Lee GA, Mafong DD, Noor MA et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004;36:645-647.
26. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947-953.
27. Noor MA. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications. Curr HIV /AIDS Rep. 2007;4:126-134.
28. Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV /AIDS Rep. 2005;2:39-50.
29. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251-20254.
30. Hertel J, Struthers H, Horj CB, et al. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem. 2004;279:55147-55152.
31. Woerle HJ, Mariuz PR, Meyer C, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes. 2003;52:918-925.
32. Stanley TL, Joy T, Hadigan CM, et al. Effects of switching from lopinavir/ ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS. 2009;23:1349-1357.